Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Feb 12, 2025
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation
Read more at globenewswire.com
